SCHEMBL4718684

SCHEMBL4718684

Cc1csc(-c2cc(Nc3cccc4cnccc34)ncn2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 1/20 0.47
ALDH1A1 P00352 7/20 0.43
MAPT P10636 5/20 0.43
KDM4E B2RXH2 5/20 0.43
KMT2A Q03164 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.41
MEN1 O00255 2/20 0.40
KDR P35968 4/20 0.39
INSR P06213 1/20 0.38
LCK P06239 1/20 0.38
LYN P07948 1/20 0.38
SRC P12931 1/20 0.38
TRPV1 Q8NER1 5/20 0.37
LMNA P02545 1/20 0.37
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36
PDE4B Q07343 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4718686 0.82 ALDH1A1 (0.48) CCR4ALDH1A1MAPTKDM4EKMT2A
SCHEMBL4720736 0.82 ALDH1A1 (0.47) CCR4ALDH1A1MAPTKDM4EKMT2A
SCHEMBL4716052 0.79 PDE4B (0.51) CCR4ALDH1A1MAPTKDM4EKMT2A
SCHEMBL4716399 0.78 KDR (0.47) CCR4ALDH1A1KDRTRPV1PDE4B
SCHEMBL4718729 0.77 CCR4 (0.43) CCR4ALDH1A1MAPTKDM4EKMT2A
SCHEMBL4718692 0.77 TRPV1 (0.49) CCR4ALDH1A1MAPTKDM4EKDR
SCHEMBL4719637 0.76 TRPV1 (0.48) CCR4ALDH1A1MAPTKDM4EKMT2A
SCHEMBL4716401 0.76 TRPV1 (0.48) CCR4ALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL4717106 0.76 TRPV1 (0.43) CCR4ALDH1A1MAPTKDM4EKMT2A
SCHEMBL4718504 0.76 TRPV1 (0.59) CCR4ALDH1A1MAPTKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 CCR4 366/4885ALDH1A1 2473/4885MAPT 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.